ADMA Q1 2023 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$57M+95.6% YoY

Gross Profit

$17M29.0% margin

Operating Income

-$813,000-1.4% margin

Net Income

-$7M-11.9% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+13.9%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$17M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$341M

Total Liabilities

$195M

Stockholders' Equity

$146M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$57M	$29M	+95.6%
Gross Profit	$17M	$4M	+350.9%
Operating Income	-$813,000	-$15M	+94.5%
Net Income	-$7M	-$25M	+72.9%

Revenue Segments

ADMA BioManufacturing Segment

$50M87%

Plasma Collection Centers Segment

$7M13%

Corporate Segment

$35,7080%

Geographic Segments

United States

$53M100%